Protocol Ledger

NCT06699212 · Phase III · RECRUITING

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Interventional Phase III clinical trial protocol NCT06699212 sponsored by Rakuten Medical in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-24 Enrollment: 412 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06699212
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)412 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06699212
Protocol FieldVerified Registry Value
NCT IdentifierNCT06699212
Consolidated Lead SponsorRakuten Medical
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment412 participants (ESTIMATED)
Registered Start Date2024-12-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06699212
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
University of MiamiMiami, FLOpen Hospital Dossier ->
Tampa General HospitalTampa, FLOpen Hospital Dossier ->
Rhode Island HospitalProvidence, RIOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI